BioSig Technologies Reinvests in Lafayette College’s InternShift Progam

Santa Monica, CA, Nov. 20, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company’s Founder, Chairman & CEO Kenneth Londoner is making a gift to Pennsylvania-based Lafayette College in order to support the school’s growing internship program. 

Mr. Kenneth L. Londoner ’89, Chairman and CEO of BioSig Technologies, Inc, was the founding alumnus to help start the school’s transformative InternShift program in 2014. Together with the College, BioSig pioneered and successfully developed a highly immersive internship experience which gives students an opportunity to enhance their professional interests in an entrepreneurial environment. During their summers at BioSig, Lafayette students work on a range of advanced projects, from researching novel therapies and clinical study breakthroughs, to preparing business plans and stock pitch decks, to analyzing international healthcare landscapes and policy standards. To address the ongoing student debt crisis, interns get paid to offset their living expenses and tuition fees.

“We are very passionate about providing our future generations with exciting opportunities to launch their careers. We hope to encourage our interns to try new things and learn real valuable work skills in anticipation of joining a rapidly changing work environment. Lafayette College is doing a tremendous job in connecting their students with the opportunities to learn applicable skills that are valuable in current and future work endeavors, and we are very happy to provide both our employment and financial support to such a great cause,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.

“BioSig Technologies’ unique InternShift experience sets an aspirational standard for all employers. Thank you for providing these immersive experiences for so many Lafayette students. You challenged others to join BioSig Technologies in preparing the next generation of employees to make a difference for our world,” commented Mrs. Alison R. Byerly, President of Lafayette College. 

About Lafayette College
Lafayette College is a private liberal arts college based in Easton, Pennsylvania. Founded in 1826, the College offers a Bachelor of Arts in 37 fields and a Bachelor of Science in 14 fields, including 4 in engineering. Lafayette College lists Diversity & Inclusion, Sustainability and Community Engagement as its core values. The student body comes from 48 countries.

About BioSig Technologies
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace ( Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market.

The Company’s first product, PURE EP™ System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision- making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. 

Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
12600 Hill Country Blvd R-275
Austin, TX 78738


Source: BioSig Technologies, Inc.